Results of an open multicenter study of theefficiency of one-week antihelicobacter therapy using omeprazole, clarithromycin, and amoxycillin in patients withduodenal peptic ulcer


Cite item

Full Text

Abstract

Aim. To study the efficiency of one-week antihelicobacter therapy using omeprazole, clarithromycin,
and amoxycillin in patients with duodenal peptic ulcer during its recurrence.
Materials and methods. 105 patients with recurrent peptic ulcer and a not less than 0.5-cm ulcer in
the duodenal bulb was given triple therapy: omeprazole, 20 mg twice daily, amoxycillin, 1000 mg twice
sidaily, and clarithromycin, 500 mg twice daily for 7 days. Then the patients were allowed to take antacids if they were required to abolish the symptoms of recurrent peptic ulcer. H. pylori was detected in
the mucosal biopsy specimens taken from the anthral part and body of the stomach at gastroduodenoscopy, by using the rapid urease test and histology. Gastroduodenoscopy was performed before and 4-6
weeks after the triple therapy.
Results. The major symptoms of recurrent peptic ulcer were eliminated in 90% of the patients by the
end of a course of therapy, i.e. on its day 7. By the control time, the rate of ulcer cicatrization was
99.05% (104/105). The coincidence of results of the two tests has indicated that H. pylori eradication
was 81.9% (86/105) 4-6 weeks after termination of treatment. Adverse reactions during therapy were
observed in 20% of the patients; however, treatment had to be discontinued only in 2.9% of the patients.
Conclusion. One-week triple therapy using omeprazole, clarithromycin, and amoxycillin is highly effective in treating duodenal peptic ulcer during its recurrence.

References

  1. Исаков В. А., Домарадский И. В. Хеликобактериоз. М.: Медпрактика-М; 2003.
  2. Malfertheiner P., Megraud F, O'Morain С. et al. Current concepts in the management of Helicobacter pylori infection the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Then 2002; 16 (2): 167-180.
  3. Vakil N., Fennerty M. B. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ul-cer. Am. J. Gastroenterol. 1996; 91: 239-245.
  4. Jonsson B. Cost-effectiveness of Helicobacter pylori eradication therapy in duodenal ulcer disease. Scand. J. Gastroenterol. 1996; 31 (suppl. 215): 90-95.
  5. Campbell L. M. The role of a Helicobacter pylori eradication regimen (omeprazole plus amoxycillin) in the long-term management of ulcer-like dyspepsia in general practice. Br. J. Med. Econ. 1994; 7: 147-153.
  6. Sonnenberg A., Schwartz S., Cutler A. F. et al. Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomised, doubleblind multicenter trial. Arch. Intern. Med. 1998; 58: 852-860.
  7. Карпов О. И. Фармакоэкономика язвенной болезни. Взгляд из Санкт-Петербурга. Эксперим. и клин, гастроэнтерол. 2003; 5: 79-82.

Copyright (c) 2003 Isakov V.A., Maev I.V., Simanenkov V.I., Kononov A.V., Abdulkhakov R.A., Zakharova N.V., Livzan M.A., Predvechnaya I.K.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

 

© 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies